BR112019025736A2 - uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue - Google Patents

uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue Download PDF

Info

Publication number
BR112019025736A2
BR112019025736A2 BR112019025736-5A BR112019025736A BR112019025736A2 BR 112019025736 A2 BR112019025736 A2 BR 112019025736A2 BR 112019025736 A BR112019025736 A BR 112019025736A BR 112019025736 A2 BR112019025736 A2 BR 112019025736A2
Authority
BR
Brazil
Prior art keywords
asthma
eosinophilic
antibody
severe
moderate
Prior art date
Application number
BR112019025736-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Jahanara AZMI
Jonathan STEINFELD
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112019025736A2 publication Critical patent/BR112019025736A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112019025736-5A 2017-06-06 2018-05-08 uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue BR112019025736A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762515641P 2017-06-06 2017-06-06
US62/515641 2017-06-06
US201862619206P 2018-01-19 2018-01-19
US62/619206 2018-01-19
PCT/US2018/031518 WO2018226339A1 (en) 2017-06-06 2018-05-08 Biopharmaceutical compositions and methods for pediatric patients

Publications (1)

Publication Number Publication Date
BR112019025736A2 true BR112019025736A2 (pt) 2020-06-30

Family

ID=64566261

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025736-5A BR112019025736A2 (pt) 2017-06-06 2018-05-08 uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue

Country Status (7)

Country Link
US (2) US11390671B2 (https=)
EP (1) EP3634467A4 (https=)
JP (2) JP7295038B2 (https=)
CN (2) CN119632921A (https=)
BR (1) BR112019025736A2 (https=)
CA (1) CA3064859A1 (https=)
WO (1) WO2018226339A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
KR20210145187A (ko) * 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
ES3057414T3 (en) * 2020-12-22 2026-03-02 Glaxosmithkline Ip Dev Ltd Interleukin 5 binding protein dosage regimen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
ZA898322B (en) 1988-11-03 1990-11-28 Schering Corp Method of preventing or reducing eosinophilia
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5858089A (en) 1997-08-26 1999-01-12 Martinovic; Zoran Corn buttering tool
TR200001117T2 (tr) 1997-10-22 2000-09-21 Ponikau Jens Mukozal dokudaki enflomasyonu önlemek ve tedavi etmek için maddeler ve yöntemler.
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JP4597643B2 (ja) 2004-11-24 2010-12-15 富士フイルム株式会社 電子内視鏡
JP2010526088A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
JP5035153B2 (ja) 2008-07-14 2012-09-26 市光工業株式会社 車両用灯具
CN107837395A (zh) 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients

Also Published As

Publication number Publication date
JP2020522524A (ja) 2020-07-30
JP7295038B2 (ja) 2023-06-20
WO2018226339A1 (en) 2018-12-13
US20200157206A1 (en) 2020-05-21
JP2023113883A (ja) 2023-08-16
US11390671B2 (en) 2022-07-19
CA3064859A1 (en) 2018-12-13
CN119632921A (zh) 2025-03-18
US20220380451A1 (en) 2022-12-01
EP3634467A4 (en) 2021-07-28
EP3634467A1 (en) 2020-04-15
US12286472B2 (en) 2025-04-29
CN110913887A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
US11976113B2 (en) Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins
TWI780988B (zh) 生藥組成物
US12286472B2 (en) Biopharmaceutical compositions and methods for pediatric patients
US12083161B2 (en) Treating IgE-mediated allergic diseases
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
BR122024020400A2 (pt) Composição e uso de uma composição
RU2800765C2 (ru) ЛЕЧЕНИЕ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
BR122025011033A2 (pt) Composição que compreende um anticorpo anti-il-5, uso terapêutico da mesma, bem como composição farmacêutica que compreende a dita composição
BR122025011067A2 (pt) Composição que compreende um anticorpo anti-il-5 e composição farmacêutica que compreende a dita composição

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024020400-2 PROTOCOLO 870240083911 EM 01/10/2024 16:53.